Multiple treatment cycles of neural stem cell delivered oncolytic adenovirus for the treatment of glioblastoma

Jennifer Batalla-Covello, Hoi Wa Ngai, Linda Flores, Marisa McDonald, Caitlyn Hyde, Joanna Gonzaga, Mohamed Hammad, Margarita Gutova, Jana Portnow, Tim Synold, David T. Curiel, Maciej S. Lesniak, Karen S. Aboody, Rachael Mooney

Research output: Contribution to journalArticlepeer-review

1 Scopus citations

Abstract

Tumor tropic neural stem cells (NSCs) can improve the anti-tumor efficacy of oncovirotherapy agents by protecting them from rapid clearance by the immune system and delivering them to multiple distant tumor sites. We recently completed a first-in-human trial assessing the safety of a single intracerebral dose of NSC-delivered CRAd-Survivin-pk7 (NSC.CRAd-S-pk7) combined with radiation and chemotherapy in newly diagnosed high-grade glioma patients. The maximum feasible dose was determined to be 150 million NSC.CRAd-Sp-k7 (1.875 × 1011 viral particles). Higher doses were not assessed due to volume limitations for intracerebral administration and the inability to further concentrate the study agent. It is possible that therapeutic efficacy could be maximized by administering even higher doses. Here, we report IND-enabling studies in which an improvement in treatment efficacy is achieved in immunocompetent mice by administering multiple treatment cycles intracerebrally. The results imply that pre-existing immunity does not preclude therapeutic benefits attainable by administering multiple rounds of an oncolytic adenovirus directly into the brain.

Original languageEnglish
Article number6320
JournalCancers
Volume13
Issue number24
DOIs
StatePublished - Dec 1 2021

Keywords

  • Glioma
  • Immunotherapy
  • Neural stem cell
  • Oncolytic virus
  • Stem cell carrier
  • Viral delivery

Fingerprint

Dive into the research topics of 'Multiple treatment cycles of neural stem cell delivered oncolytic adenovirus for the treatment of glioblastoma'. Together they form a unique fingerprint.

Cite this